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Abstract 
Background  
During pregnancy women might weigh benefits of treatment against potential risks to the unborn child. However, 
non-adherence to necessary treatment can adversely affect both mother and child. To optimize pregnant women’s 
beliefs and medication adherence, community pharmacists are ideally positioned to play an important role in 
primary care.  
 
Objective  
This narrative review aimed to summarize the evidence on 1) pregnant women’s beliefs, 2) medication adherence 
in pregnancy, and 3) community pharmacists’ counselling during pregnancy. 
 
Method  
Three search strategies were used in Medline and Embase to find original studies evaluating women’s beliefs, 
medication adherence and community pharmacists’ counselling during pregnancy. All original descriptive and 
analytic epidemiological studies performed in Europe, North America and Australia, written in English and 
published from 2000 onwards were included.  
 
Results  
We included 14 studies reporting on women’s beliefs, 11 studies on medication adherence and 9 on community 
pharmacists’ counselling during pregnancy. Women are more reluctant to use medicines during pregnancy and 
tend to overestimate the teratogenic risk of medicines. Risk perception varies with type of medicine, level of 
health literacy, education level and occupation. Furthermore, low medication adherence during pregnancy is 
common. Finally, limited evidence showed current community pharmacists’ counselling is insufficient. Barriers 
hindering pharmacists are insufficient knowledge and limited access to reliable information.  
 
Conclusion  
Concerns about medication use and non-adherence are widespread among pregnant women. Community 
pharmacists’ counselling during pregnancy is insufficient. Further education, training and research are required 
to support community pharmacists in fulfilling all the opportunities they have when counselling pregnant women.  
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1. Introduction 
During pregnancy, a substantial number of women have pregnancy-related disorders or preexisting morbidities 
which may require pharmacological treatment. Although prevalence estimates of medication use during 
pregnancy vary between studies, it is well established that maternal use of medicines is common during this period 
[1-3]. Recent studies have shown that eight out of ten women take at least one prescription or over-the-counter 
(OTC) medicine during pregnancy [4], with paracetamol being the most common OTC exposure (65%) [5, 6]. 
Medication use during pregnancy poses important challenges to the women and their physicians, since the benefits 
of pharmacological treatment have to be weighed against potential risks to the unborn child. Although 
teratogenicity has been shown for some medicines such as thalidomide, isotretinoin and valproic acid [7-9], safety 
data for more subtle pregnancy outcomes and for longer-term effects on child development remain scarce. Still, 
medicines are frequently needed during pregnancy, for example to treat pre-existing conditions like asthma or 
epilepsy, acute conditions like infections or fever, or to treat pregnancy-related disorders like nausea and vomiting, 
hypertension or gestational diabetes.  
 
Prior research has shown that at least half of the pregnant women need information about medicines during 
pregnancy [10]. Unfortunately, inaccurate information and inconsistencies between sources has been observed, 
potentially leading to increased and unjustified anxiety among pregnant women, unrealistic risk perception of 
drug exposure, or even abrupt discontinuation of needed pharmacotherapy [6, 11-13]. Because non-adherence to 
necessary pharmacotherapy can adversely affect both mother and child, understanding its extent across various 
diseases in pregnancy is essential for fetal-maternal health.  
 
From a societal point of view, there are many reasons for utilizing pharmaceutical expertise in community 
pharmacy care of pregnant women. Firstly, antenatal care in most countries does not provide prenatal care until 
gestational weeks 8-12 [14]. Despite this, women can experience pregnancy-related ailments prior to their first 
consultation (typically nausea and vomiting) [15], making pharmacists the first healthcare professionals pregnant 
women encounter. Furthermore, previous studies have reported that pregnant women rely on pharmacists as one 
of the most used sources of information about medicines during pregnancy [6, 10]. Due to their easy accessibility 
and wide distribution in the community, pharmacists are ideally positioned to play an important role in primary 
pregnancy care. In addition, studies in non-pregnant patients have shown the effectiveness of pharmacists’ 
counselling on medication adherence, persistence, clinical management and therapeutic outcomes [16-22]. This 
is important since two recent studies have shown medication-related problems (MRP) frequently occur among 
pregnant women [23, 24]. These MRP were largely resolved by pharmacists correcting misperceptions, providing 
information, and empowering the women to make safe decisions about medication use [23]. The potential 
contribution of pharmacists to improve fetal-maternal health has been recognized by the International 
Pharmaceutical Federation (FIP), stating that pharmacists can detect the use of potential teratogenic medicines 
and counsel pregnant women on alternative medicines [25]. In order to take up this role, pharmacists need to 
maintain and improve professional performance. Therefore, pharmacy education and continuous professional 
development are essential to optimize pharmacists’ knowledge, communication skills and problem-solving 
competencies.   
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From a global public health perspective, safe and rationale medication use during pregnancy is essential to 
improve fetal-maternal health, and this can be accomplished via a better understanding of pregnant women’s 
beliefs and barriers to optimal medication adherence. Likewise, knowledge about current pharmacists’ counselling 
practice and about the barriers they experience in counselling is useful to further develop the profession. 
Therefore, this narrative review aimed to summarize quantitative evidence on the following three aspects: 1) 
pregnant women’s beliefs about medicines and risk perception; 2) pregnant women’s medication adherence and 
persistence in real-world setting; 3) and community pharmacists’ counselling practice during pregnancy and the 
barriers they encounter. In the discussion, future perspectives with regard to pharmaceutical care research, 
continuous education and undergraduate training are provided.  
 
2. Methods 
Three search strategies were used in MEDLINE and EMBASE in May 2018 to find original studies evaluating 
beliefs about medicines and medication adherence among pregnant women as well as community pharmacists’ 
counselling during pregnancy. MeSH and Emtree terms and text words were used to retrieve relevant articles. 
Reference lists of identified studies were examined in order to identify other potential articles. An overview of 
the concepts (combined via AND) and corresponding search terms (combined via OR) for each of the three search 
strategies can be found in the Supplementary Material.  
 
All original descriptive and analytic epidemiological studies from Europe, North America and Australia, written 
in English and published from 2000 onwards were included. Reviews, Delphi studies, qualitative research, case 
reports and case series, editorials and commentaries, and conference abstracts were excluded. For the topic 
‘medication adherence’, only studies describing one of the following aspects were included: adherence and 
persistence; acute and chronic medicines; adherence prevalence estimates and factors associated with low 
adherence. Studies exploring medication discontinuation in pregnancy were not included. Clinical trials on 
adherence to HIV treatment during pregnancy, and pharmacists’ counselling related to contraception and 
emergency contraception, vitamin use and lifestyle changes (smoking or alcohol cessation) were beyond the scope 
of the manuscript as well.  
 
Two reviewers (MC & AL) independently selected the retrieved articles based on inclusion and exclusion criteria. 
Discrepancies in judgement were evaluated by a third independent reviewer (VF) to reach consensus on the final 
list of included articles. Of these, full texts were collected and read in full.  
For each review section, we extracted data on authors, publication year, study country, study period, data source, 
study population, study type and design, number of study participants, main outcome measure and main findings.  
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3. Results  
 
3.1 Beliefs about medicines among pregnant women 
A total of 504 studies were initially retrieved in the literature search. After application of the exclusion criteria 
and removing duplicates, we identified 14 papers on beliefs about using medicines during pregnancy (see Table 
1). These studies were conducted in a variety of countries with Norway producing four papers and on a variety of 
therapeutic areas. The number of participants in the studies ranged from 95 – 8131 pregnant or recently pregnant 
(within 5 years) women. The most prevalent data collection method was a self-completed questionnaire distributed 
either in person or via a website aimed at pregnant women. Different measures were used ranging from scales as 
the Beliefs about Medicines (BMQ; measuring beliefs about medicines in general and during pregnancy), to 
Visual Analogue Scales (VAS; measuring risk perception), as well as self-generated questions.  
 
Most studies found that women were more reluctant to use medicines during pregnancy and tended to overestimate 
the teratogenic risk of medicines. Willingness to initiate or continue medication use, however, depended on their 
severity of illness and whether they were pregnant or had recently delivered at the time they reported on beliefs 
about medicines in pregnancy [26-32]. The most common fear in using medicines during pregnancy appeared to 
be the risk of harming the unborn child [6, 27, 29, 30]. The framing of this information appeared important for 
the overall assessment of risk [33], while the first person to give participants this information was more likely to 
influence their final decision [34].  
 
Overall, there appears to be high consistency within the studies that women with a lower literacy and education 
levels overestimate the teratogenic risk of medicines to a greater extent than their counterparts [28, 35-37]. Only 
one study did not support this finding [6]. Two studies indicated that women who were healthcare professionals 
rated the risk of taking medicines during pregnancy lower than those with no healthcare background or occupation 
[28, 37].  
 
The majority of studies highlighted that the perceived risk of taking medicines during pregnancy does not apply 
to all categories of medicines equally. In these studies, women frequently reported antidepressants and anxiolytics 
as those with the highest risk, and antibiotics and paracetamol with the lowest risk or greatest benefit [27, 35, 37, 
38]. 
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Table 1: Characteristics and main findings of included studies related to ‘beliefs about medicines’.  
Authors & 
publication year 
Country & period Study population Study type & design, 
N 
Main measure  
 
Main findings 
EUROPE 
Duggan et al. 
2014 [36] 
Ireland, 2012 Pregnant women 
attending the antenatal 
clinic at Cork 
University Hospital 
antenatal unit between 
4th – 24th January 2012  
 
Cross-sectional 
questionnaire study 
 
N = 404 
REALM and BMQ Lower level of education and lower literacy level 
associated with stronger beliefs about the harm of 
medicines.  
Heitmann et al. 
2016 [26] 
Norway, 2014/15 Pregnant women and 
women with a child ≤ 
1 year old. 
Experienced nausea or 
vomiting in most 
recent pregnancy 
Cross-sectional  
web-based 
questionnaire study 
 
N = 712 
Self-generated 
questions on attitudes 
towards medicines 
Women who were more likely to use medicines 
thought that it was better for the fetus to use 
medicines and get better than leave the illness 
untreated.  
 
Majority of women reported a higher threshold for 
using medicines while being pregnant. 
 
Severity of symptoms was an important 
consideration for taking medicines. 
 
The majority of women taking conventional 
medicines were anxious about the effect on the 
fetus and used less than required as a result. 
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Authors & 
publication year 
Country & period Study population Study type & design, 
N 
Main measure  
 
Main findings 
Mulder et al. 
2018 [27] 
Netherlands, 2013 Pregnant women 
attending a Dutch 
obstetric care facility 
Cross-sectional  
self-reported 
questionnaire study 
 
N = 136 
Self-generated 
questions on risk 
perception 
Pregnant women were most concerned about birth 
defects, miscarriage or giving birth to a child with 
an allergic disease as a result of their drug use.  
 
Highest perceived risk for antidepressants, 
sedatives and NSAIDs. Highest benefit for 
antibiotics, antifungals and antacids.  
 
Risk perception was highest in the first two 
trimesters. 
 
No other demographics influenced perceived risk. 
Lower benefit scores correlated with being single, 
smoking, nulliparous and no family history of birth 
defects.  
 
Nordeng et al. 
2010 [28] 
Norway, 2008 Currently pregnant 
women  
Self-completed 
structured web-based 
questionnaire 
 
N = 866 
Part BMQ plus self-
generated study 
specific questions 
Most women were more cautious taking medicines 
during pregnancy. 
 
A large proportion believed that even if ill they 
should abstain from taking medication they would 
have otherwise taken if not pregnant.  
 
Physicians consent needed prior to taking natural 
remedies (majority of respondents).  
 
Education and occupation (health related versus 
non-health related) appeared to have some impact 
on beliefs.  
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Authors & 
publication year 
Country & period Study population Study type & design, 
N 
Main measure  Main findings 
Nordeng et al. 
2010 [6] 
Norway, 2008 Pregnant women and 
women with a child ≤ 
5 years old 
Self-completed 
structured web-based 
questionnaire 
 
N = 1793 
Self-generated 
questions on risk 
perception 
The majority of women (87.5%) estimated correctly 
that the general risk of malformation is ≤5%. Most 
women, however, overestimated the risks of drugs 
and other exposures during pregnancy. 
Risk was perceived as highest for smoking, alcohol, 
sedatives/anxiolytics and antidepressants.  
 
Higher perceived risk from women who were older, 
had a higher level of education, choosing not to use 
a drug during pregnancy and primiparity.  
 
Most common reason for not using a drug was fear 
of harming the unborn child.  
 
76.6% reported they needed information on drug 
use and 60% found this information conflicting 
between different sources.  
 
Twigg et al. 2016 
[29]* 
UK, 2011/12 Pregnant women and 
women with a child ≤ 
1 year old 
Self-completed 
structured web-based 
questionnaire 
 
N = 1120 
BMQ plus self-
generated questions 
on risk perception 
72.8% of women reported avoiding the use of 
medicines during pregnancy. 
 
Most common reasons for avoiding were: fear of 
harming the unborn child, medication not 
recommended and stating that they would endure as 
much as possible before taking medicines.  
 
Women who did not take medication perceived 
greater risk than those who did take medicines.  
 
46.3% required more information about medicines 
use in pregnancy.  
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Authors & 
publication year 
Country & period Study population Study type & design, 
N 
Main measure  
 
Main findings 
Widnes et al., 
2013 [38] 
Norway, 2010/11 Women attending a 
regular ultrasound scan 
in week 17-19 of 
pregnancy and their 
associated general 
practitioner (GP) 
Self-completed 
questionnaire study 
 
Women: N = 171  
GPs: N= 74  
Self-generated 
questions on 
medicine labels 
Out of 6 medicines (5 conventional and 1 herbal) 
participants thought paracetamol and 
dexchlorpheniramine were the safest. 
 
GPs gave a lower risk score than pregnant women. 
 
Little confidence in the herbal preparation.  
 
Scores for the clarity of the explanatory text 
indicated the text was appropriately phrased. 
  
Patel et al., 2012 
[30] 
UK, 2012 Nulliparous and 
multiparous women 
requiring antenatal 
therapy with 
enoxaparin in a 
hematological clinic 
 
Self-administered 
questionnaire 
 
N = 95 
BMQ Perceived necessity of enoxaparin antenatally 
outweighed concerns. 
 
88.4% stated enoxaparin not an issue as long as 
their baby’s health was protected.   
 
 
 
CANADA        
Jasper et al., 2001 
[33] 
Canada, 2001 Successive callers to 
the Motherisk Program 
telephone pregnancy 
information line 
Telephone structured 
interview 
 
N = 105 
Self-generated 
questions on risk 
perception 
Negatively framing information about fetal risk 
increases the perception of teratogenicity and the 
likelihood of not wanting to take the drug.  
 
Women who received positively framed 
information had a lower risk perception. 
 
 
 
 10 
Authors & 
publication year 
Country & period Study population Study type & design, 
N 
Main measure  Main findings 
Bonari et al., 
2005 [34] 
Canada, 2004 Three groups of 
Motherisk Program 
telephone callers 
taking 1) 
antidepressants, 2) 
gastric medicines and 
3) taking short term 
antibiotics 
 
Before and after 
questionnaire and 
interview study 
 
N = 100 in each group 
Risk perception 
analogue scale & 
CES-D  
Pre-counselling: 87% (antidepressants), 56% 
(gastric) and 22% (antibiotics) of women rated the 
risk of medicines as greater than 1-3%.  
 
Significant decrease in risk perception from before 
to after the counselling service.  
 
15% chose to discontinue antidepressant regardless 
of advice from Motherisk 
 
The first opinion received by the participants 
regarding safety appeared to be an important 
influence towards the eventual decision to continue 
or discontinue therapy.  
 
Demographics did not correlate with the decision to 
continue therapy.  
USA        
Goodman, 2009 
[31] 
USA, 2006/7 Convenience sample of 
women in their third 
trimester attending an 
obstetric clinic 
Self-administered 
questionnaire 
 
N = 509 
Self-generated 
questions on risk 
perception 
For the treatment of depression only 35.6% put 
medication as a top three option. Only 7.3% would 
consider this as first choice. 
 
66% thought that taking medication for depression 
whilst pregnant was probably not or definitely not 
acceptable.  
 
Those who had used psychotropic medication 
before and had lower depression scores were more 
likely to say that medication use was acceptable.  
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Abbreviations: REALM=Rapid Estimate of Adult Literacy in Medicine; BMQ=Beliefs about Medicines questionnaire; CES-D=Center for Epidemiologic Studies Depression 
Scale; IBD=Inflammatory Bowel Disease; *all part of the same data collection – studies presented here represent different sub-analyses of the data.
Authors & 
publication year 
Country & period Study population Study type & design, 
N 
Main measure  Main findings 
AUSTRALIA 
Selinger et al., 
2013 [32] 
Australia, 2012 Female patients with 
IBD aged 18-45 from 
two tertiary outpatient 
IBD clinics 
Self-administered 
questionnaire 
 
N = 145 
Self-generated 
questions on risk 
perception 
The majority of women stated that all medicines for 
IBD should be avoided during pregnancy. 
However, a majority also stated that if medicines 
are controlling symptoms they should be continued 
during pregnancy.  
 
Negative attitudes towards medicines and 
symptoms were associated with lower pregnancy-
related knowledge scores.  
 
MULTINATIONAL 
Petersen et al., 
2015 [37]* 
Multi-national, 
2011/12 
Pregnant women and 
women with a child ≤ 
1 year old 
Self-completed 
structured web-based 
questionnaire 
 
N = 8131 
Self-generated 
questions on risk 
perception 
Rated antidepressants, alcohol, smoking and 
thalidomide as most harmful. 
 
Lower education level had higher perceptions of 
risk.  
 
Female healthcare professionals had a lower 
perception of risk.  
 
Some geographic differences in risk perception. 
 
Lupattelli et al., 
2014 [35]* 
Multi-national, 
2011/12 
Pregnant women at any 
gestational age 
Self-completed 
structured web-based 
questionnaire 
 
N = 4999 
Self-generated 
questions on risk 
perception 
Women with low health literacy reported higher 
risk perceptions for medicines and more negative 
beliefs about medicines.  
 
Antidepressants were given the highest risk rating. 
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3.2 Medication adherence during pregnancy 
A total of 275 studies were initially retrieved in the literature search. After application of the exclusion criteria 
and removing duplicates, 11 studies on medication adherence in pregnancy were identified (see Table 2). All 
studies were observational either based on primary (7 studies) or secondary data sources (2 studies) or both (2 
studies). A single study explored the consequence of low medication adherence on pregnancy outcomes [39]. The 
remaining ten studies were descriptive, reporting prevalence of medication adherence and risk factors for low 
adherence. Most studies had a small sample size (42-804 women). Medication adherence was mainly measured 
via self-reported instruments such as the Morisky Medication Adherence Scale (MMAS) or as percentage of filled 
prescriptions (%), with a threshold of 80% for low/high adherence.  
 
Two studies explored medication adherence in the context of maternal depression [40, 41]. Rates of low adherence 
to prescribed antidepressants were 45.0 and 48.8%. In both studies, low adherence was positively associated with 
greater severity of maternal psychiatric symptoms. Two studies explored adherence to progesterone or 
acetylsalicylic acid for prevention of adverse pregnancy outcomes [39, 42]. Low adherence was 33.7 to 46.3% 
for progesterone or acetylsalicylic acid, respectively, and no maternal risk factors were identified. Five studies 
explored medication adherence in the context of treatment of somatic disorders such as asthma, cardiovascular 
and inflammatory disorders [30, 43-46]. In one of those studies reporting adherence to heparin injections in 
women with thrombotic disorders, adherence rate was as high as 97.9% [30]. Another study showed that, under a 
special treatment management program, medication adherence to asthma medication was 73.0% [45]. Low 
medication adherence was commonly reported by pregnant women treated for rheumatic or inflammatory diseases 
(range 32.8-55.6%), as well as in women treated for epilepsy (40.0%) [43, 44, 46]. A single study explored 
medication adherence in the context of hypothyroidism in pregnancy [47]. Here, 16.9% of pregnant women 
demonstrated low medication adherence. The one study from Australia reported low medication adherence as a 
pooled estimate for a range of different disorders, which was found as high as 59.1% [48].  In the sole claims-
based US study exploring the consequence of low medication adherence in pregnancy, there was no statistically 
significant association between adherence to progesterone and rates of prematurity, but study power was low [39].  
 
Maternal characteristics (i.e., age, parity, smoking, lack of the use of folate, personality traits), women’s beliefs 
and perceptions on medication exposure, and not least specialist counselling about continuation of medical 
treatment in pregnancy, seemed to be important determinants of medication adherence in pregnancy [40, 43, 44, 
46, 47]. These factors were differentially associated with medication adherence depending on the type of maternal 
disease.  
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Table 2: Characteristics and main findings of included studies related to ‘medication adherence’.  
 
Authors & 
publication year  
Country & 
period 
Data source Study population Study type & 
design, N 
Main 
measure 
Therapeutic 
area 
Main findings 
EUROPE 
Baarnes et al., 
2016 [45] 
Denmark 
2012 
Outpatient 
clinical 
records within 
the ‘asthma 
management 
program’ and 
self-
completed 
questionnaire 
Pregnant women 
referred to the 
outpatient 
respiratory clinic, 
with diagnosed 
asthma and 
prescribed 
bronchodilators 
Descriptive, 
prospective 
cohort 
 
N = 114 
Self-reported 
adherence, and 
MPR 
Asthma Self-reported adherence: 73% 
MPR: 46%  
 
Significant positive association between 
self-reported adherence and MPR. 
Abheiden et al., 
2016 [42] 
Netherlands 
2015-2016 
Tertiary 
university 
hospital 
records and 
self-reported 
paper-based 
questionnaire 
Pregnant women 
with an indication 
for use of low-
dose 
acetylsalicylic 
acid 
Descriptive, 
cross-sectional 
 
N = 42 
SMAQ 
BBQ 
Prevention of 
recurrent 
hypertension 
and fetal growth 
restriction  
Self-reported adherence: 
SMAQ non-adherence: 46.3% 
BBQ non-adherence: 21.4% 
 
No association between adherence and 
age, race, BMI, education, maternal 
disease or indication. 
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Authors & 
publication year  
Country & 
period 
Data source Study population Study type & 
design, N 
Main 
measure 
Therapeutic 
area 
Main findings 
Patel et al., 2012 
[30] 
Unspecified 
country and 
period, 
probably UK 
Self-reported 
diary and 
paper-based 
questionnaire 
Pregnant women 
referred to the 
hematology clinic 
in need of 
enoxaparin 
Descriptive, 
prospective 
cohort 
 
N = 95 
Adherence 
rate ≥ 80% 
according to 
self-completed 
diaries with 
times of 
injection, 
verified 
through 
laboratory 
tests  
VTE, anti-
phospholipid 
syndrome, 
switch from 
long-term 
warfarin 
High adherence=97.9% 
 
No association of adherence with race, 
history of recurrent miscarriage, and 
frequency of the injections. 
Julsgaard et al., 
2011 [44] 
Denmark 
2000-2006a 
 
National 
Registries 
(Patient, 
Medical Birth, 
Prescription) 
and self-
reported 
paper-based 
questionnaire 
Pregnant women 
with ulcerative 
colitis having 
given birth in 
2000–2005 
Descriptive, 
retrospective 
cohort 
 
N = 62 
Adherence 
rate ≥ 80% 
consumption 
of prescribed 
medicines 
Ulcerative 
colitis 
High adherence: 59.7% 
Significant negative association of low 
adherence with receiving counselling 
regarding medical treatment. No 
association of low adherence with 
multiparity, unplanned pregnancy, and 
smoking. 
Nielsen et al., 
2010 [43] 
Denmark 
2000-2006a 
 
National 
Registries 
(Patient, 
Medical Birth, 
Prescription) 
and self-
reported 
paper-based 
questionnaire 
 
 
Pregnant women 
with Crohn 
disease having 
given birth in 
2000–2005 
Descriptive, 
retrospective 
cohort 
 
N = 55 
Adherence 
rate ≥ 80% 
consumption 
of prescribed 
medicines 
Crohn disease High adherence: 67.3% 
Significant negative association of low 
adherence with multiparity and having 
planned the pregnancy. No association of 
low adherence with receiving 
counselling regarding medical treatment.  
 15 
Authors & 
publication year  
Country & 
period 
Data source Study population Study type & 
design, N 
Main 
measure 
Therapeutic 
area 
Main findings 
USA 
Hydery et al., 
2017 [39] 
USA 
2011-15 
Administra-
tive claim 
records, 
Massachusetts 
Medicaid  
Pregnant women 
filling 
progesterone 
prescriptions in 
Massachusetts 
Analytical, 
retrospective 
cohort  
 
N = 169 
Adherence as 
PCD of ≥ 0.8  
Prevention of 
premature birth  
High adherence=66.3%  
Term vs. preterm delivery: 
PCD ≥ 0.8: 58.0% vs 42.0% 
PCD< 0.8: 70.2% vs 29.8% 
p=0.124 
No association between adherence and 
race, type and number of comorbidities.  
 
Wu et al., 2014 
[41] 
USA 
2004-2009 
Administra-
tive claim 
records, South 
Carolina 
Medicaid 
Pregnant women 
with a depression 
diagnosis within 
280 days prior to 
delivery 
Descriptive, 
retrospective 
cohort 
  
N = 804 
Non-
persistence, as 
a 2 week gap 
between 
consecutive 
prescriptions  
Depression Non-persistence to treatment: 45.0%  
Non-persistence was significantly, 
positively associated with nonwhite race, 
antidepressant use in the year prior to 
pregnancy, and number of office visits. 
Non-persistence was negatively 
associated with hospitalization. 
 
AUSTRALIA 
Sawicki et al., 
2011 [48] 
Australia 
2009 
 
Self-reported 
paper-based 
questionnaire 
Pregnant women 
attending the 
outpatient clinics 
of RWH  
Descriptive, 
cross-sectional 
 
N = 181 
MMAS-4 Asthma, blood-
related 
disorders, 
diabetes, 
vitamin/mineral 
deficiencies,  
hypertension 
 
 
 
 
 
Self-reported low adherence: 59.1% 
High adherence: 40.9% 
 
Significant, positive association of low 
adherence with having asthma, and using 
non-prescribed dietary minerals. 
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Authors & 
publication year  
Country & 
period 
Data source Study population Study type & 
design, N 
Main 
measure 
Therapeutic 
area 
Main findings 
MULTINATIONAL 
Juch et al., 2016 
[47]*  
Multi-
national with 
18 countries 
2011-2012 
Web-based, 
self-
completed 
questionnaire 
Pregnant women 
with self-reported 
hypothyroidism 
Descriptive, 
cross-sectional 
 
N = 213 
MMAS-8 Hypothyroidism Self-reported adherence: Low=16.9%, 
Medium=44.1%, High=39.0% 
 
Significant, positive association of low 
adherence with younger maternal age, 
and no use of folic acid. 
Higher adherence significant positively 
correlated with conscientious personality 
and perception that the benefit of 
pharmacotherapy outweighed the risks. 
 
Lupattelli et al., 
2015 [40]*  
Multi-
national with 
18 countries 
2011-2012 
Web-based, 
self-
completed 
questionnaire 
Pregnant women 
with self-reported 
psychiatric 
disorders 
Descriptive, 
cross-sectional 
 
N = 160 
MMAS-8 Depression, 
anxiety, other 
psychiatric 
disorders 
Self-reported adherence: Low=48.8%, 
Medium=35.6%, High=15.6% 
 
Significant positive association of low 
adherence with smoking during 
pregnancy, elevated antidepressant risk 
perception, and depressive symptoms; 
negative association with psychotropic 
polytherapy.  
Higher adherence positively correlated 
with the perception that the benefit of 
pharmacotherapy outweighed the risks. 
Lupattelli et al., 
2014 [46]*  
Multi-
national with 
18 countries 
2011-2012 
Web-based, 
self-
completed 
questionnaire 
Pregnant women 
with self-reported 
somatic chronic 
disorders  
Descriptive, 
cross-sectional 
 
N = 210 
MMAS-8 Somatic chronic 
disorders: 
cardiovascular, 
rheumatic, 
bowel disorders, 
diabetes, 
epilepsy 
Overall self-reported low adherence: 
36.2%  
 
Adherence, cardiovascular disorders: 
Low=32.9%, Medium=35.4%, 
High=31.7% 
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Authors & 
publication year  
Country & 
period 
Data source Study population Study type & 
design, N 
Main 
measure 
Therapeutic 
area 
Main findings 
Adherence, rheumatic disorders: 
Low=55.6%, Medium=28.9%, 
High=15.5% 
 
Adherence, bowel disorders: 
Low=36.1%, Medium=27.8%, 
High=36.1% 
 
Adherence, diabetes: Low=17.1%, 
Medium=45.7%, High=37.2% 
 
Adherence, epilepsy: Low=40.0%, 
Medium=44.0%, High=16.0% 
 
Significant, positive association of low 
adherence with multiparity, no folic acid 
use, and beliefs that it is better to abstain 
from medicines or use herbals during 
pregnancy. No association of adherence 
with region of residency and FDA-
assigned pregnancy categories D/X 
 
Abbreviations: MPR=medical possession rate; SMAQ=simplified medication adherence questionnaire; BBQ= Beliefs and Behaviour Questionnaire; VTE=Venous 
thromboembolism; PCD=proportion of days covered; RCT=Randomized Clinical Trial; NPV=Nausea and vomiting of pregnancy; PUQE= delta of pregnancy unique-
quantification of emesis score; RWH= The Royal Women’s Hospital; MMAS-4=4 items Morisky Medication Adherence Scale; MMAS-8=8 items Morisky Medication 
Adherence Scale; FDA=Food and Drug Administration; ain these two studies, women giving birth between 2000 and 2005, having the disease of interest, were first selected. 
In 2006, they received a paper-based postage questionnaire; *all part of the same data collection – studies presented here represent different sub-analyses of the data.
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3.3 Community pharmacists’ counselling of pregnant women  
A total of 310 studies were initially retrieved in the literature search. After application of the exclusion criteria 
and removing duplicates, we obtained only four studies evaluating pharmacists’ counselling practice during 
pregnancy. Three of these studies were published more than 10 years ago. As shown in Table 3, all studies were 
descriptive and cross-sectional with samples of 110-276 pharmacists, mainly practicing in community 
pharmacies. Three out of four studies presented various scenarios to pharmacists and questioned them about their 
counselling on pharmacological as well as non-pharmacological treatment, and referral to a physician [49-51]. 
Differences were observed between pharmacists in Serbia, Norway and France in response to common ailments 
[49, 50]. OTC medicines were recommended by the majority of pharmacists (>60%) in treatment of pain and 
common cold symptoms including sore-throat, runny nose and fever [49-51]. Recommendation of homeopathy 
was the most prevalent response among French pharmacists to treat allergic rhinitis (>70% of participants) and 
cough (>50% of participants) [50]. In several scenarios, referring to a physician was the most prevalent 
suggestion: heavy legs and back pain (>63% of pharmacists in Norway), and morning sickness (>57% of 
pharmacists in France) [49, 50].   
One multinational study in the Netherlands, Canada and Iceland investigated pharmacist’s behavior upon a visit 
of a mystery patient asking for information about specific drug use related to pregnancy. Referral to a physician 
has been suggested by most pharmacists (90-100%) upon questions with regard to fluoxetine use in week 6 of 
pregnancy and with regard to metronidazole and carbamazepine use by women planning to get pregnant [52].  
 
Five studies were identified specifically targeting barriers and concerns pharmacists experience when counselling 
pregnant women (see Table 4). All studies were descriptive with regard to concerns and barriers; some also 
included information on facilitators. Four studies used self-completed questionnaires to collect information. The 
number of pharmacists involved in these studies ranged from 43-472. Different barriers and areas of concerns, 
including symptoms and products of concern, related to the counselling of pregnant women have been identified. 
Gaps in knowledge about treatment of specific conditions in pregnancy and inadequate undergraduate knowledge-
base were the most frequently reported barriers [53-55]. Additionally, two papers reported inaccessibility and 
absence of information related to medicines’ use during pregnancy as a common problem [55, 56].  
 
The study by Hutchinson has shown that “experiential education” (experience gained in practice) contributed to 
knowledge about OTC medicines counselling in pregnancy [55]. Continuing professional development courses 
have also been recognized as very important to increase the knowledge base related to this specific issue [53, 55]. 
A more recent assessment of the use and perceived added-value of a helpline for pharmacists (teratology 
information service Motherisk, developed in Canada) showed it is a good example of quickly providing needed 
information to pharmacists related to safety issues in pregnancy [57].  
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Table 3: Characteristics and main findings of included studies related to the level of pharmacists’ counselling of pregnant women.  
Authors & 
publication year 
Country & 
period 
Data source Study 
population 
Study type & design, 
N 
Main measure Main findings 
EUROPE 
Odalovic et al., 
2016 [49] 
Serbia 2012; 
Norway 
2014  
Web-based, 
self-completed 
questionnaire 
Community 
and hospital 
pharmacists  
Descriptive,  
cross-sectional 
 
N = 276  
 
  - Serbia: 119 
  - Norway: 157  
Level of counselling 
of medicine (M), 
supplement (S),  
non-pharmacological 
treatment (NPhT), 
referral to physician 
(RP)  
Serbia 
back pain: 5.3% (S) – 71.2% (M)   
heavy legs: 10.1% (RP) – 49.9% (NPhT) 
nausea: 11.8% (S) – 50.5% (M)   
common cold: 8.4% (RP) – 63.8% (M) 
constipation: 1.4% (RP) – 54.5% (NPhT) 
 
Norway 
back pain: 0% (S) – 63.7% (RP)   
heavy legs: 1.3% (S) – 71.3% (RP)  
nausea: 13.4% (M) – 70.7% (NPhT) 
common cold: 12.1% (RP) – 80.9% (M) 
constipation: 11.5% (S) – 92.4% (M) 
   
Damase-Michel 
et al., 2004 [50] 
France  
1999  
Face-to-face 
interview   
with paper-
based open 
questionnaire 
Community 
pharmacists 
and pharmacy 
technicians  
Descriptive,  
cross-sectional 
 
N = 130  
Level of counselling 
of homeopathy (H), 
phytotherapy (Ph), 
allopathy (A),    
non-pharmacological 
treatment (NPhT),  
referral to physician 
(RP) 
back pain: 0.8% (Ph) – 83.8% (A)   
headache: 0% (Ph) – 93.8% (A)   
sore-throat: 2.4% (NPhT) - 60.3% (A)   
runny nose: 0% (Ph) – 66.4% (A)   
dry cough: 0.8% (Ph, NPhT) – 80.3% (H)   
productive cough: 1.6% (Ph, NPhT) – 50.8% (H)   
fever and aches: 0.8% (NPhT) – 75.4% (A)   
constipation: 0% (RP) – 93.8% (A) 
morning sickness: 0.8% (Ph) – 57.7% (RP) 
heartburn: 0% (Ph) – 88.5% (A) 
heavy legs: 3.1% (H) – 85% (NPhT): 
allergic rhinitis, 1st trim: 0% (Ph) – 73.0% (H) 
allergic rhinitis, 3rd trim: 0% (Ph) – 74.6% (H) 
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Abbreviations: OTC=over the counter 
 
 
Authors & 
publication year 
Country & 
period 
Data source Study 
population 
Study type & design, 
N 
Main measure Main findings 
Lyszkiewicz et 
al., 2001 [52] 
Netherlands, 
Canada, 
Iceland 
 
Period 
unknown 
Mystery 
shopper with 
standardize 
data collection 
form 
completed 
immediately 
upon leaving 
the pharmacy   
Community 
pharmacists 
and pharmacy 
technicians 
Descriptive, cross-
sectional 
 
N = 120 (40/country) 
Level of counselling 
of stop the drug (SD), 
continue the drug 
(CD), referral to 
physician (RP)  
Fluoxetine (pregnancy week 6):  
SD: 10-25% 
CD: 10-35% 
RP: 90-100% 
 
Metronidazole (planning of pregnancy):  
SD: 10-70% 
CD: 0-40% 
RP: 90-100% 
 
Carbamazepine (planning of pregnancy):  
SD: 0-5% 
CD: 5-30% 
RP: 65-100% 
 
USA 
Schrempp et al., 
2001 [51] 
Nebraska 
1998- 1999 
Self-
completed 
questionnaire 
Community 
pharmacists 
Descriptive, cross-
sectional 
 
N = 110 
Level of counselling 
of OTC product; 
pharmacists comfort 
level with counselling 
of pregnant women; 
factors that influence 
pharmacists’ 
counselling    
cough: 45% 
cold: 43% 
analgesic: 62% 
laxative: 46% 
diarrhea: 36% 
insomnia: 17% 
heartburn: 56% 
 
There were no statistical differences in 
counselling frequencies by geographic region, 
gender, academic degree (doctorate in pharmacy; 
bachelor in science), and age   
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Table 4: Characteristics and main findings of included studies related to pharmacists’ barriers and areas of concerns when counselling pregnant women.  
Authors & 
publication year 
Country & 
period 
Data source Study 
population 
Study type & 
design, N 
Main measure Therapeutic 
area  
Main findings  
EUROPE 
Hutchinson et al., 
2001 [55] 
Scotland 
Period 
unknown 
Structured 
telephone 
interview 
Community 
pharmacists 
 
Descriptive, 
cross-sectional  
 
N = 43 
Pharmacists areas 
of concern, 
knowledge base 
for counter- 
prescribing* in 
pregnancy, 
additional 
information 
readily accessible  
All Symptoms of concern: 
congestion, flu-like symptoms, ingestion 
in last trimester, pain from broken lag, 
recurring headache, sickness, thrush. 
 
Products of concern: 
Analgesia stronger than paracetamol, or 
requests for codeine/paracetamol or 
ibuprofen, antihistamines, ranitidine, 
herbals. 
 
Barriers: 
Gaps in undergraduate knowledge: 67% 
did not feel that undergraduate education 
contributed to their knowledge base for 
counter-prescribing* in pregnancy. 
 
The most used reference source was BNF 
(91%), but deficit in information has been 
reported about drugs use during 
pregnancy. 
 
Zehnder et al., 
2004 [56] 
Switzerland  
2001 
Web-based, 
self-completed 
questionnaire 
Community 
pharmacists 
 
Descriptive, 
cross-sectional  
 
N = 108 
Types of drug 
information used 
by pharmacists in 
daily practice 
All Barriers: 
The most used reference source was Swiss 
drug reference book, but deficit in 
information has been reported about drugs 
use during pregnancy. 
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Authors & 
publication year 
Country & 
period 
Data source Study 
population 
Study type & 
design, N 
Main measure Therapeutic 
area  
Main findings  
CANADA 
Tan et al., 2011 
[57] 
Canada  
2009-2010 
Standardized 
form for data 
collection 
from calls 
received by 
Teratogenic 
information 
service (TIC) 
 
Pharmacists, 
pharmacists’ 
assistants, 
technicians, 
pharmacy 
students who 
calls TIC 
 
 
Descriptive 
 
N = 472 calls 
Types of calls 
received 
All  Products of concern: antibiotics (14.3%), 
gastrointestinal drugs (13.5%) and 
psychiatric drugs (9.3%) 
 
Products of safety concerns: steroids (40 
calls); SSRI/SNRI (33 calls); 
nitrofurantoin (18 calls), opioids (15 calls) 
USA  
McAuley et al., 
2009 [54] 
Ohio  
Period 
unknown 
Self-
completed  e-
questionnaire  
 
Community 
and hospital 
pharmacists 
Descriptive, 
cross-sectional 
 
N = 152 
Pharmacists 
knowledge  
Epilepsy Barriers: 
Gaps in knowledge:  
More than 70% of pharmacists correctly 
answered four of the six pregnancy-related 
statements (folic acid= 77%, healthy 
babies=83%, continued AED adherence 
during pregnancy=87%, choice of AED 
during pregnancy=71%. 
 
Pharmacists who interacted with the most 
patients per month had the highest scores. 
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Abbreviations: BNF=British National Formulary; TIC=Teratogenic Information Service; SSRI/SNRI=Selective Serotonin/Norepinephrine Reuptake Inhibitor; AED=anti-
epileptic drugs; *Counter-prescribing: pharmacists prescribing products over-the-counter without reference to a physician prescription.    
Authors & 
publication year 
Country & 
period 
Data source Study 
population 
Study type & 
design, N 
Main measure Therapeutic 
area  
Main findings  
MULTINATIONAL 
Bains et al., 2014 
[53] 
Canada, 
Uganda and 
Qatar 
2012-2013 
Web-based, 
self-completed 
questionnaire 
Community, 
hospital, and 
academia 
pharmacists 
and resident 
pharmacists 
Descriptive, 
cross-sectional 
 
N = 273 
Pharmacists 
knowledge, 
training 
opportunities and 
resources 
available related 
to fetal-maternal 
medicines 
All Barriers: 
Mean knowledge assessment score of 
pharmacists in Canada, Qatar and Uganda 
were 63%, 53% and 58%, respectively.  
 
Gaps in undergraduate knowledge: 
71% (Canada), 48% (Qatar) and 56% 
(Uganda) of pharmacists indicated that 
they had obtained instruction or training in 
fetal-maternal medicine throughout their 
undergraduate program.  
 
Gaps in undergraduate knowledge: 
27% (Canada), 52% (Qatar) and 33% 
(Uganda) of pharmacists (strongly) agreed 
that their entry-to-practice degree provided 
sufficient training to respond to drug 
information requests and to care for 
patients with issues related to fetal-
maternal medicine.  
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4. Discussion  
4.1 Main findings 
This review provides important insights into pregnant women’s beliefs and medication adherence, as well as in 
community pharmacists’ counselling of pregnant patients. The available evidence suggests that pregnant women 
have a high threshold for using medicines during pregnancy [26, 28, 29]. Similar to studies among non-pregnant 
women [58-60], individual negative beliefs and high risk perception of drug exposure are important predictors of 
medication avoidance during pregnancy [26, 29]. Heitmann et al. in 2016 found more positive beliefs towards 
medicines among pregnant women who took them; this is in line with the observation of Twigg et al. in 2016 who 
found lower risk perception scores among women using medicines in pregnancy than women not using medicines. 
Furthermore, risk perception seemed to vary with the type of medicine, level of health literacy, education level 
and occupation [27, 28, 35-38]. Overall, the most common fear in using medicines during pregnancy appeared to 
be the risk of harming the unborn child [6, 27, 29]. This finding underlines the fact that pregnancy is a unique 
situation where the individual takes both maternal and fetal health into consideration.  
 
With regard to medication adherence during pregnancy, low adherence was common, although rates varied 
substantially between studies and indications. Only one study reported high adherence rates among more than 
80% of pregnant study participants [30]. Of note, studies addressing the consequences of poor medication 
adherence in pregnancy on fetal-maternal health are almost non-existing, suggesting an urgent need of more 
research in this area. Moreover, the available literature suggests that low medication adherence during pregnancy 
is of special concern among women with psychiatric, rheumatic, or bowel disorders, and not least among women 
with epilepsy. While low adherence for rheumatic or bowel disorders may be explained by a quiescent phase of 
these disorders in pregnancy, the suboptimal treatment of psychiatric disorders or even epilepsy during pregnancy, 
deserves clinical attention. In one qualitative study, women taking antiepileptic drugs had restrictive attitudes 
towards taking medicines for indications other than epilepsy [61]. This shows that in pregnancy women may rank 
the importance of their chronic/acute conditions, and adequately medicate only one of those. 
 
Multiple studies reported a positive association between unfavorable maternal characteristics (i.e., smoking, lack 
of the use of folate) and low medication adherence [40, 46, 47], despite variations were evident depending on the 
pharmacological treatment considered. Nevertheless, as also shown in the non-pregnant population [62], women’s 
beliefs about their prescribed medicines were consistently found to be the most important determinants of 
medication adherence [40, 46, 47]. Specialist counselling about continuation of drug treatment during pregnancy 
played an important role in the context of adherence for treatment of bowel disorders [44], but was not so in 
relation to Crohn disease [43].  
 
Counselling is essential to reduce concerns and correct misperceptions about medicines in pregnancy. According 
to Bonari in 2005, telephone advice of Canadian pregnant women by trained teratology information specialists 
significantly reduced women’s risk perception [34]. Interestingly, the way the information is transferred to the 
women is also important [63], as positively framed information has been associated with lower perception of risk 
[33]. Pharmacists are often the first health care professionals (HCPs) pregnant women meet. Since the first person 
a pregnant woman speaks with regarding the use of medicines might have the greatest impact on her decision 
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[34], community pharmacists play an important role to optimize medication use during pregnancy. However, the 
limited evidence presented in the current review shows that community pharmacists’ practice with regard to 
counselling pregnant women on safe and effective medicines’ use, as observed in the studies, is still insufficient 
[49-52]. Pharmacists hesitate to advise medicines for common ailments during pregnancy, recommend less 
appropriate products and refer frequently to a physician, without taking any responsibility. Barriers hindering 
pharmacists to bring pharmaceutical care into daily practice were insufficient knowledge on the topic and limited 
access to reliable information [53-56]. The differences in pharmacists’ counselling observed between countries 
might be due to differences in availability of products and in regulation and duration of pharmacy undergraduate 
programs. 
 
When searching for reliable information or support on safe medicines during pregnancy, several high-quality 
websites are freely available to pharmacists. These include evidence-based resources and national teratology 
information services such as www.mothertobaby (Organisation of Teratology Information Specialists), 
www.uktis.org (UK), www.motherisk.org (Canada), www.lareb.nl (The Netherlands), www.janusinfo.se 
(Sweden), www.tryggmammamedisin.no and www.relis.no (SafeMommyMedicine, Norway), www.lecrat.fr 
(France) and www.cybele.be (Belgium). A recent report has shown that such information services can quickly 
provide needed information to pharmacists [57]. However, such services do not exist in every country yet. 
Establishing a recognized reference center in each country was urged for by the European Board and College of 
Obstetricians and Gynecologists (EBCOG) in 2016 [64]. Additionally, EBCOG also recommended the 
elaboration of research on the safe use of medicines in pregnancy.  
 
4.2 Methodological considerations 
To our knowledge, the current review is the first attempt to discuss pregnant women’s beliefs, risk perception and 
medication adherence in relation to community pharmacists’ counselling during pregnancy. In order to collect 
suitable references, English written articles published from 2000 onwards were derived from databases Medline 
and Embase. Only studies conducted in Europe, North America and Australia were eligible for inclusion. 
Qualitative studies, reviews, Delphi studies, case reports and case series, editorials, commentaries, and conference 
abstracts were excluded. The quality of the individual studies and risk of bias across studies was not assessed 
specifically. Most studies on medication adherence and beliefs relied on women’s self-enrollment in the study, 
and thus the risk of selection bias cannot be ruled out. It is therefore possible that our summarized results may in 
fact represent an underestimation of the true prevalence of low medication adherence and negative medication 
beliefs in pregnancy. Indeed, the sample of the included studies more often included women with higher education 
than the general birthing population in the country. This should be kept in mind when interpreting the results. 
Generally, the paucity of published studies on beliefs about medicines and medication adherence during 
pregnancy makes is difficult to draw sound conclusions, especially given the small sample sizes and the 
heterogeneity of study methods utilized. This has barely improved since previous reviews on medication 
adherence during pregnancy were published in 2012 [65, 66]. The application of different study methods also 
prevents efficient comparison of study findings [67]. Another limitation is that this was a review of quantitative 
studies, and therefore provides no insight into women’s motives of negative beliefs and/or drivers for low 
medication adherence. Lastly, only four studies on community pharmacists’ counselling practice were found; 
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three of those were published more than 10 years ago. The included studies on barriers were performed in different 
settings with low numbers of participants, hence limiting the generalizability of the findings.  
 
Importantly, none of the included scales or instruments were specifically tailored to pregnancy nor validated in 
that population. These findings emphasize the urgent need to develop psychometric instruments that can validly 
measure medication adherence among pregnant women. The development, validation and implementation of 
pregnancy-specific questionnaires for studies evaluating women’s beliefs is also encouraged, e.g. continuing on 
the pregnancy-specific statements of the Beliefs about Medicines Questionnaire that was developed by Nordeng 
in 2010 [28]. The use of these instruments could allow international comparison of data, including the impact of 
cultural beliefs, socio-demographic backgrounds and organization of health care on beliefs and risk perception. 
Future initiatives should also study the consequences of (unjustified) negative beliefs about medicines on 
medication adherence during pregnancy, and as previously mentioned, of low adherence on maternal and child 
pregnancy outcomes. The development, implementation and evaluation of strategies to reduce concerns, correct 
misperceptions and improve medication adherence during pregnancy is warranted.   
 
4.3 Implications 
The results from this review not only have clinical implications for community pharmacists, but for all HCPs. All 
HCPs should be aware of pregnant women’s beliefs and perceptions about medicines during pregnancy. Negative 
beliefs on medicines and low health literacy can impair medication adherence and, consequently, fetal and 
maternal well-being. Given the unique situation of a pregnancy, women will balance their decisions about 
medication use between personal benefits of treatment and the potential harmful effect of medicines on the unborn 
child. Hence, pregnant women should be encouraged to discuss their beliefs and concerns with HCPs. Equally 
important, HCPs need to provide evidence-based information regarding medicines in pregnancy and to provide 
counselling to prevent misperception about medicines and overestimation of teratogenicity. In case a woman who 
is planning to get pregnant uses chronic medicines, counselling needs to be initiated prior to conception 
(‘preconception care’).  
 
The findings presented in the current review clearly emphasize the major opportunities for pharmaceutical care 
research, continuous evidence-based education and undergraduate training with regard to medication counselling 
during pregnancy. So far, no randomized controlled studies on the impact of interventions to improve community 
pharmacists’ knowledge, competencies and/or counselling practice related to pregnancy have been performed. 
However, training of pharmacists’ counselling competencies has been shown to positively affect the quality of 
patient care [68]. Hence, pregnancy-related interventions, using blended learning programs, need to be developed 
and tested. Assessment of community pharmacists’ performance in a real-life context using mystery shoppers 
should be considered [52, 69]. These interventions should be performed in controlled studies, either with a before-
after or RCT design.  
 
The results further call upon universities and on professional organizations involved in continuous professional 
development of community pharmacists. In order to overcome the barriers and areas of uncertainty, universities 
and organizations should focus more on fetal-maternal medicine and corresponding pharmacotherapy in their 
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courses. Academic assessment of counselling competencies can be performed using Objective Structured Clinical 
Examinations (OSCE) [70]. OSCEs have been highly recommended for competency assessments and evaluate 
higher stages of performance [71-73] .  
 
 
5. Conclusion  
This review has found that concerns about medication use in pregnancy and non-adherence are widespread among 
pregnant women. The limited evidence also shows that community pharmacists’ counselling practice during 
pregnancy is insufficient, with insufficient knowledge and limited access to reliable information as main barriers. 
Furthermore, there is an urgent need for research and development of methods tailored to measure adherence and 
beliefs about medicines in pregnancy. As easily accessible health care professionals, community pharmacists play 
an important role in primary care by correcting misperceptions, providing evidence-based information, optimizing 
medication adherence and empowering pregnant women to make safe decisions about medication use, especially 
related to minor ailments and OTC medicines. However, the current review suggests that further education, 
training and research are required in order to support community pharmacists in fulfilling all the opportunities 
they have when counselling pregnant women.  
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Supplementary Material 
 
Overview of the concepts and corresponding search terms for the three search strategies.  
 
 Beliefs about medicines Medication adherence Pharmacists’ counselling 
Concept 1 Pregnancy; Pregnant Women; 
Pregnancies, Gestation  
Pregnancy; Pregnant Women; 
Pregnancies, Gestation  
Pregnancy; Pregnant Women; 
Pregnancies, Gestation  
Concept 2 Prescription Drugs; 
Nonprescription Drugs; 
Pharmaceutical Preparations; 
Drugs; Medicines; 
Medication, Medication usage 
Prescription Drugs; 
Nonprescription Drugs; 
Pharmaceutical Preparations; 
Drugs; Medicines; 
Medication, Medication usage 
Pharmacist; Pharmacists; 
Community Pharmacist; 
Community Pharmacists; 
Pharmacy; Community 
Pharmacy Services 
Concept 3 Beliefs about medication; 
Beliefs about medicines; 
Beliefs about medicines 
questionnaire; Perception; 
Risk perception; Health 
knowledge, attitudes, practice; 
Attitude to health;  
Medication adherence; 
Medication nonadherence; 
Medication persistence; 
Medication compliance; 
Medication non-compliance; 
Drug persistence   
Counseling; Counselling; 
Patient Counseling; Role; 
Education; Pharmacy 
education; Pharmaceutical 
education; Education, 
pharmacy; Education, 
pharmacy, continuing; 
Continuing education; Patient 
simulation 
 
 
